Romosozumab biosimilar(Zhuhai Federation Biomedicine)

罗莫佐单抗生物类似药（珠海联邦生物）

Report date: 2025/09/30 11:14:41
First In Class

Base Information

Drug NameRomosozumab biosimilar(Zhuhai Federation Biomedicine)
Drug Alias NameRomosozumab-AQQG罗莫组单抗Romosozumabum洛莫索珠单抗罗莫索单抗 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionSclerostin inhibitors
TargetsSclerostin
Therapy Area/IndicationsOsteoporosis, Postmenopausal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhuhai Federation Biomedicine Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhuhai Federation Biomedicine Co Ltd
Inactive CompaniesN/A
Active IndicationsOsteoporosis, Postmenopausal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG